Asian Free Trade Deal Could Strengthen Canadian Patent Rights, PhRMA Says
This article was originally published in PharmAsia News
Executive Summary
Brand industry hopes weaknesses in Canada’s intellectual property regime, including lack of patent term restoration and a higher patent utility standard for biopharmaceutical products, could be addressed through the 11-nation talks on a Trans-Pacific Partnership agreement.